Trial Profile
BAY 94-9172 PET/CT in Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 27 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2025.
- 11 Feb 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.